D. Frye

发表

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

G. Hortobagyi, N. Sneige, V. Valero, 2011, The oncologist.

Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

G. Hortobagyi, A. Buzdar, A. González-Angulo, 2004, Clinical breast cancer.

Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature

V. Valero, N. Ibrahim, R. Theriault, 2014, Journal of Cancer.

Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.

G. Hortobagyi, S. Singletary, H. Kuerer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine: nursing implications of a new oral chemotherapeutic agent.

D. Frye, M. Mrozek-Orlowski, H. Sanborn, 1999, Oncology nursing forum.

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

G. Hortobagyi, S. Singletary, F. Ames, 1997, Cancer Chemotherapy and Pharmacology.

A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of 10-EDAM in the treatment of metastatic breast cancer

G. Hortobagyi, D. Booser, A. González-Angulo, 2007, Cancer Chemotherapy and Pharmacology.

Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer.

G. Hortobagyi, V. Valero, D. Booser, 2008, Clinical breast cancer.

Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy

Terry L. Smith, G. Hortobagyi, R. Theriault, 1999, Cancer.

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

G. Hortobagyi, V. Valero, N. Ibrahim, 2006, Cancer Chemotherapy and Pharmacology.

The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy

G. Hortobagyi, R. Theriault, A. Buzdar, 1989, Cancer.

Phase II evaluation of gallium nitrate by continuous infusion in breast cancer

G. Hortobagyi, F. Holmes, K. Jabboury, 1989, Investigational new drugs.

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

G. Hortobagyi, A. Buzdar, G. Hortobagyi, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.